SMART-101 is under clinical development by Smart Immune and currently in Phase II for Refractory Acute Myeloid Leukemia.

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Relapsed Acute Myeloid Leukemia.

SY-001 is under clinical development by CellOrigin Technology (Hangzhou) and currently in Phase I for Pancreatic Cancer.

EBBH-2024 is under clinical development by Essen Biotech and currently in Phase II for Diffuse Large B-Cell Lymphoma.

DVX-201 is under clinical development by Coeptis Therapeutics and currently in Phase I for Myelodysplastic Syndrome.

CX-801 is under development for the treatment of metastatic solid tumors including metastatic melanoma, metastatic renal cell carcinoma (RCC) and head and neck squamous cell carcinoma (HNSCC). It is a ...

CYTO-102 is under clinical development by CytoImmune Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer.

Ulecaciclib is under clinical development by Aucentra Therapeutics and currently in Phase II for Cervical Cancer.

Not Disclosed Neuroscience and Pain 2 is under clinical development by Evotec and currently in Phase I for Unspecified Neurologic Disorders.

BNT-162b1 is under clinical development by BioNTech and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Dexamethasone sodium phosphate is under clinical development by AVM Biotechnology and currently in Phase II for Metastatic Pancreatic Cancer.

TB-006 is under clinical development by TrueBinding and currently in Phase II for Autism Spectrum Disorder (ASD).